Drug Approval | March 21, 2022
Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
Subscribe To Our Newsletter & Stay Updated
